COMBINATION TREATMENT

Abstract

The invention proposes a combination comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or its pharmaceutical salt or solvate; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other anticancer drug. The invention also proposes a method for treating subjects diagnosed with hematopoietic disorders using these combinations. These compounds are represented by Formula (Ϊ) as follows: where R¹a, R¹b, R², R³, R⁴, U, Y¹, X¹, X², n1, n2, n3 and n4 are defined in this description.